Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9-Mediated Induction of Relapse-Specific NT5C2 and PRPS1 Mutations Confers Thiopurine Resistance as a Relapsed Lymphoid Leukemia Model.

Molecular pharmacology - 1 Apr 2023

Nguyen Thao Thu Thi, Tanaka Yoichi, Sanada Masashi, Hosaka Masumi, Tamai Minori, Kagami Keiko, Komatsu Chiaki, Somazu Shinpei, Harama Daisuke, Kasai Shin, Watanabe Atsushi, Akahane Koushi, Goi Kumiko, Inukai Takeshi

Abstract excerpt

6-Mercaptopurine (6-MP) is a key component in maintenance therapy for childhood acute lymphoblastic leukemia (ALL). Recent next-generation sequencing analysis of childhood ALL clarified the emergence of the relapse-specific mutations of the NT5C2 and PRPS1 genes, which are involved in thiopurine metabolism. In this scenario, minor clones of leukemia cells could acquire the 6-MP-resistant phenotype as a result of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5'-Nucleotidase
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mercaptopurine

Share to Mutation

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Recurrence

Source

Identifiers

PMID: 36669880
DOI: 10.1124/molpharm.122.000546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9-Mediated Induction of Relapse-Specific NT5C2 and PRPS1 Mutations Confers Thiopurine Resistance as a Relapsed Lymphoid Leukemia Model.PMID 36669880Read ↗

Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.Semantic proximity Read ↗

Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.Semantic proximity Read ↗

Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.Semantic proximity Read ↗

High-Throughput CRISPR Screening in Hematological NeoplasmsSemantic proximity Read ↗

FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Thiopurine Resistance in Childhood ALL Is Mediated by PRPS1 Mutations.Semantic proximity Read ↗

In silico identification of deleterious NT5C2 and PRPS1 mutations driving thiopurine resistance in relapsed acute lymphoblastic leukemia.Semantic proximity Read ↗

Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia†.Semantic proximity Read ↗

Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line.Semantic proximity Read ↗

Repair of leukemia-associated single nucleotide variants via interallelic gene conversionSemantic proximity Read ↗

Acquired thiopurine resistance and mismatch repair aberrations in paediatric B-cell acute lymphoblastic leukaemia relapse: A real-world data integrating mutational signatures, clones and clinical thiopurine dosing patterns.Semantic proximity Read ↗

Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.